Solutions Ecosystems Reports Resources Data Pricing Login Book a demo
Power Law company profile

Ultragenyx Pharmaceutical

Biotech & Life Sciences · Novato, United States · Founded 2010 · IPO 2014 Unicorn

Treatment of rare and ultra-rare diseases, with an initial focus on serious, debilitating metabolic genetic diseases

Valuation
$1.78B
Market cap · May/2026
Revenue
$673M
Latest reported FY
Featured in Unicorn$1B+ valuation tier · Power Law dataset 2026 $10B+ revenueThoroughbred · Power Law outcome

Investors

7 investors on Ultragenyx Pharmaceutical's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series A 2 investors entered at this stage
Takeda Ventures
TPG
Series B+ 5 investors entered at this stage
HealthCap
F-Prime
Pappas Capital
TPG Growth
RA Capital Management

Global footprint

Where Ultragenyx Pharmaceutical has talent and traffic

AI talent share
0.1% of workforce is AI talent
(1 of 1,533 staff)
Core AI00%
Other AI10.07%
Non-AI workforce1,53299.93%
Workforce by country
21 countries with
team presence
🇺🇸 United States83.2%
🇧🇷 Brazil3.9%
🇨🇭 Switzerland2.6%
🇲🇽 Mexico1.5%
🇦🇷 Argentina1.4%
Top 5 of 21 shown
Web traffic by country
46K monthly visits
across markets
🇺🇸 United States55.7%
🇮🇳 India6.5%
🇯🇵 Japan5.4%
🇬🇧 United Kingdom4.3%
🇲🇽 Mexico3.9%
Top 5 markets shown

Patent intelligence

$79M patent portfolio · 49 active families

Estimated portfolio value
$79M
4.4% of market cap · 34.5× smaller than top peer Illumina ($2.7B)
49 active patent families
Where Ultragenyx Pharmaceutical innovates Adeno-associated virusMolecular biologyVirusSialic acidBioinformatics

Where Ultragenyx Pharmaceutical concentrates vs peers

Each axis is a top-10 topic across Ultragenyx Pharmaceutical and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Capital deployed

Ultragenyx Pharmaceutical's 4 investments and acquisitions.

Every disclosed deal where Ultragenyx Pharmaceutical appeared as a backer or acquirer, 2017–2024. Toggle between venture rounds, M&A, or both. The map below is grouped by the target company's sector — the colored pill on each chip is the round type.

Portfolio analysis

4 deals across Ultragenyx Pharmaceutical's capital deployment.

Where the deals concentrate by sector, stage, and decade.

By sectorCount
    By stageCount
      By periodCount

        01 · Deployment strategy vs peers

        Where Ultragenyx Pharmaceutical deploys vs peers

        Each axis is a Dealroom topic tag — picked from the cluster's most-tagged themes. Values are normalized per axis: the peer with the highest tag-coverage on that axis sits at the edge, others scale relative to them. Toggle between M&A, venture, or both.

        Compare against

        02 · Portfolio market map

        Ultragenyx Pharmaceutical's portfolio, mapped.

        Each chip is one company. Pill colour shows round type — green for Seed, blue for Series A, purple for B/C+, pink for late-stage, amber for M&A. Bigger sectors keep their full list behind “+ N more”.

        Stage
        Period
        4 of 4 deals

        Market sentiment

        What the market is saying about Ultragenyx Pharmaceutical

        An AI-synthesized read of the highest-engagement posts about Ultragenyx Pharmaceutical on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

        Reading the room on X — pulling top posts and synthesizing themes…

        Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

        See Ultragenyx Pharmaceutical on the full Dealroom platform

        Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

        Book a demo Explore company profiles